Mirati Therapeutics, Inc. (MRTX)
(Delayed Data from NSDQ)
$63.93 USD
+2.52 (4.10%)
Updated May 3, 2019 04:00 PM ET
After-Market: $64.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
MRTX 63.93 +2.52(4.10%)
Will MRTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRTX
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
MRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B